Skip to main content

Table 2 Characteristics of patients in the safety population at inclusion.

From: Randomized, multicentre assessment of the efficacy and safety of ASAQ – a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria

 

ASAQ1 group

(N = 313)

ASAQ2 group

(N = 315)

AL group

(N = 312)

Age (years)

   

   Mean ± SD

9.5 ± 10.8

9.1 ± 9.8

9.4 ± 10.7

   < 5 years

146 (46.6)

148 (47.0)

142 (45.5)

   ≥ 5 years

167 (53.4)

167 (53.0)

170 (54.5)

Gender

   

   Male

176 (56.2)

170 (54.0)

167 (53.5)

   Female

137 (43.8)

145 (46.0)

145 (46.5)

Weight (kg)

24.8 ± 18.8

24.6 ± 17.7

24.6 ± 17.4

Parasite density (/μL)

37780.9 ± 45651.6

41863.0 ± 49049.1

33958.3 ± 41473.5

Gametocyte density (/μL)*

173.1 ± 296.5

(n = 14)

256.0 ± 317.3

(n = 14)

376.0 ± 1037.2

(n = 15)

  1. ASAQ1: ASAQ 1 daily intake; ASAQ2: ASAQ 2 daily intakes; AL: AL 2 daily intakes
  2. Data are presented as mean ± SD for quantitative variables and as patient numbers (%) for categorical variables. *Information on gametocyte density is only provided for the small number of subjects (N = 43 overall) with gametocytaemia at inclusion.